🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Health Concern

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million infections per year. Particularly high rates are observed in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was authorized by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is employed against UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone represents a significant shift in the treatment of superbug gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Data and Global Access

Based on results published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The study included over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Doctors treating patients have expressed positive views. Access to a one-pill regimen such as this is seen as a "critical tool" for public health efforts. This is deemed vital to alleviate the strain of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.